Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
J Pediatr ; 216: 19-24, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31679634

RESUMEN

OBJECTIVES: To assess the relationship between self-efficacy, the belief that an individual can succeed at a goal, and short-term treatment outcome in children with functional constipation. STUDY DESIGN: Patients with functional constipation age 8-16 years completed the Self-Efficacy for Functional Constipation Questionnaire (SEFCQ), consisting of 14 statements about performing tasks needed for defecation. Patients completed SEFCQ before, immediately after, and 3 weeks after their clinic visit. Treatment success was defined as ≥3 bowel movements into the toilet and no fecal incontinence in the third week. RESULTS: 75% of patients had a successful outcome. Scores were higher in the group that was successful than in those that failed before, immediately after the visit, and 3 weeks later (P < .001). Self-efficacy improved at all time points in the group that was successful (P < .001). In the group that failed, scores improved immediately after clinic visit (P < .01) but were unchanged at follow-up (P > .05). CONCLUSIONS: Improved self-efficacy is associated with successful outcomes in children with functional constipation, thus, it may be beneficial to enhance self-efficacy for defecation during treatment.


Asunto(s)
Estreñimiento/psicología , Autoeficacia , Adolescente , Niño , Estreñimiento/terapia , Defecación , Incontinencia Fecal/prevención & control , Humanos , Encuestas y Cuestionarios , Resultado del Tratamiento
4.
Surg Obes Relat Dis ; 20(4): 354-361, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38195315

RESUMEN

BACKGROUND: Sleeve gastrectomy (SG) induces weight reduction and improves metabolic co-morbidities in children with severe obesity but remains underutilized, especially for young adolescents and preadolescents. OBJECTIVE: We hypothesized there would be no differences in weight loss or co-morbidity resolution at 1 year post-SG in children who underwent SG at 13 years or younger compared to children who underwent SG at 17-18 years old. SETTING: Academic medical center, United States. METHODS: Medical records of children who underwent laparoscopic SG at a quaternary academic center from September 2014 to October 2022 were reviewed. A cohort of 15 patients, ≤13 years of age, was compared to a matched cohort of 15 older adolescent patients. Preoperative characteristics and postoperative outcomes were collected. RESULTS: Both cohorts had similar baseline characteristics. Median preoperative body mass index (BMI) was 51.8 kg/m2 for the ≤13 cohort compared to 50.9 kg/m2 in the older cohort (P = .87). Time to postoperative enteral feeds and length of stay were similar between both groups, and there were no 30-day readmissions or immediate postoperative complications. Median percentage excess BMI loss at 1 year postoperation was 54% (IQR, 25.5%-94.5%) for the ≤13 cohort compared with 44% (IQR, 34.0%-51.0%) for the older cohort (P = .34). Two of 11 patients were lost to follow-up in the younger group compared to 4 of 15 in the older group (P = .61). Both groups demonstrated significant improvement in metabolic syndrome co-morbidities after SG. CONCLUSION: SG in younger children is associated with successful postsurgical outcomes compared with adolescents, with effective weight loss and improvement of obesity-related metabolic co-morbidities.


Asunto(s)
Laparoscopía , Obesidad Mórbida , Obesidad Infantil , Niño , Humanos , Adolescente , Estudios Retrospectivos , Obesidad Infantil/cirugía , Obesidad Infantil/complicaciones , Resultado del Tratamiento , Obesidad Mórbida/complicaciones , Obesidad Mórbida/cirugía , Índice de Masa Corporal , Gastrectomía , Pérdida de Peso
5.
JPEN J Parenter Enteral Nutr ; 46(8): 1914-1922, 2022 11.
Artículo en Inglés | MEDLINE | ID: mdl-35274342

RESUMEN

BACKGROUND: Small bowel bacterial overgrowth (SBBO) is a common, but difficult to diagnose and treat, problem in pediatric short bowel syndrome (SBS). Lack of clinical consensus criteria and unknown sensitivity and specificity of bedside diagnosis makes research on this potential SBS disease modifier challenging. The objective of this research was to describe clinical care of SBBO among international intestinal rehabilitation and nutrition support (IR&NS) providers treating patients with SBS. METHODS: A secure, confidential, international, electronic survey of IR&NS practitioners was conducted between March 2021 and May 2021. All analyses were conducted in the R statistical computing framework, version 4.0. RESULTS: Sixty percent of respondents agreed and 0% strongly disagreed that abdominal pain, distension, emesis, diarrhea, and malodorous stool, were attributable to SBBO. No more than 20% of respondents strongly agreed and no more than 40% agreed that any sign or symptom was specific for SBBO. For a first-time diagnosis, 31 practitioners agreed with use of a 7-day course of a single antibiotic, with a majority citing grade 5 evidence to inform their decisions (case series, uncontrolled studies, or expert opinion). The most common first antibiotic used to treat a new onset SBBO was metronidazole, and rifaximin was the second most commonly used. One hundred percent of respondents reported they would consider a consensus algorithm for SBBO, even if the algorithm may be divergent from their current practice. CONCLUSION: SBBO practice varies widely among experienced IR&NS providers. Development of a clinical consensus algorithm may help standardize care to improve research and care of this complex problem and to identify risks and benefits of chronic antibiotic use in SBS.


Asunto(s)
Infecciones Bacterianas , Síndrome del Intestino Corto , Humanos , Niño , Intestino Delgado/microbiología , Pautas de la Práctica en Medicina , Síndrome del Intestino Corto/microbiología , Antibacterianos/uso terapéutico , Encuestas y Cuestionarios
6.
Surg Obes Relat Dis ; 18(9): 1161-1166, 2022 09.
Artículo en Inglés | MEDLINE | ID: mdl-35753896

RESUMEN

BACKGROUND: Pediatric severe obesity is a worldwide health concern. Treatment with metabolic and bariatric surgery can reduce morbidity and mortality. The COVID-19 pandemic not only has had a significant effect on rates of pediatric obesity but also has necessitated a rapid transition to virtual medicine. OBJECTIVE: We aimed to identify and examine adolescent metabolic and bariatric surgery patient participation rates through our program's virtual telehealth programming as compared with prepandemic traditional in-person clinic appointments. SETTING: This study took place at an academic pediatric quaternary care center. METHODS: We evaluated 92 adolescent patients with a total of 2442 unique encounters between January 2018 and July 2021. RESULTS: The rate of attendance was found to be greater for telehealth visits (83.1%) than for in-person appointments (70.5%) for all clinics regardless of appointment type (preoperative versus postoperative). Cancellation rates were lower for telehealth visits (9.9%) than for in-person appointments (22.5%). CONCLUSION: This study provides evidence that telehealth can be implemented successfully in an adolescent metabolic and bariatric surgery program and can improve attendance rates for all provider and appointment subtypes.


Asunto(s)
Cirugía Bariátrica , COVID-19 , Obesidad Mórbida , Telemedicina , Adolescente , COVID-19/epidemiología , Niño , Humanos , Obesidad Mórbida/cirugía , Pandemias
7.
JPEN J Parenter Enteral Nutr ; 46(8): 1944-1947, 2022 11.
Artículo en Inglés | MEDLINE | ID: mdl-35730416

RESUMEN

BACKGROUND: Pediatric patients with intestinal failure are at increased risk for iron deficiency. Supplementation is not routinely included in parenteral nutrition solutions. There is currently limited research related to the safety of iron supplementation in parenteral nutrition and for intravenous forms used in patients with intestinal failure. Current American Society for Parenteral and Enteral Nutrition and ESPGHAN guidelines promote the use of enteral iron, acknowledging the risks of using iron supplementation within parenteral nutrition admixtures. METHODS: We review a patient case and the current available literature related to iron in parenteral nutrition. RESULTS: Five major concerns are identified: peroxidation reactions, incompatibility, hypersensitivity, infection risk, and iron overload. CONCLUSION: We propose an argument against the preferential use of iron supplementation within parenteral nutrition in children with intestinal failure when enteral supplementation or intermittent parenteral infusion may be sufficient.


Asunto(s)
Insuficiencia Intestinal , Hierro , Nutrición Parenteral , Niño , Humanos , Suplementos Dietéticos/efectos adversos , Insuficiencia Intestinal/terapia , Hierro/efectos adversos , Nutrición Parenteral/métodos , Soluciones para Nutrición Parenteral
8.
Genetics ; 177(4): 2481-91, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17947401

RESUMEN

A high-density genetic map of papaya (Carica papaya L.) was constructed using microsatellite markers derived from BAC end sequences and whole-genome shot gun sequences. Fifty-four F(2) plants derived from varieties AU9 and SunUp were used for linkage mapping. A total of 707 markers, including 706 microsatellite loci and the morphological marker fruit flesh color, were mapped into nine major and three minor linkage groups. The resulting map spanned 1069.9 cM with an average distance of 1.5 cM between adjacent markers. This sequence-based microsatellite map resolved the very large linkage group 2 (LG 2) of the previous high-density map using amplified fragment length polymorphism markers. The nine major LGs of our map represent papaya's haploid nine chromosomes with LG 1 of the sex chromosome being the largest. This map validates the suppression of recombination at the male-specific region of the Y chromosome (MSY) mapped on LG 1 and at potential centromeric regions of other LGs. Segregation distortion was detected in a large region on LG 1 surrounding the MSY region due to the abortion of the YY genotype and in a region of LG6 due to an unknown cause. This high-density sequence-tagged genetic map is being used to integrate genetic and physical maps and to assign genome sequence scaffolds to papaya chromosomes. It provides a framework for comparative structural and evolutional genomic research in the order Brassicales.


Asunto(s)
Brassicaceae/genética , Carica/genética , Mapeo Cromosómico/métodos , Evolución Biológica , Cromosomas de las Plantas , Genes de Plantas , Ligamiento Genético , Genoma de Planta , Repeticiones de Microsatélite
9.
Pediatric Health Med Ther ; 9: 129-133, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30498390

RESUMEN

BACKGROUND: Oral serum-derived bovine immunoglobulin (SBI)/protein isolate is a medical food intended to manage chronic diarrhea. It has been shown to improve pain and diarrhea in adults with diarrhea-predominant irritable bowel syndrome (d-IBS). AIM: To determine if SBI can improve symptoms in children with d-IBS. METHODS: We performed a randomized, double-blind, placebo-controlled, pilot study (NCT02609529) to evaluate the effectiveness of SBI in children 8-18 years with d-IBS. We recorded stool number, abdominal pain, and stool form in all patients for 1 week and then assigned the patients at a ratio of 2:1 to treatment with SBI 5 g BID or placebo for 3 weeks. The patients and their parents completed the Pediatric Quality of Life Inventory™ for Gastrointestinal Symptoms (PedsQOL) and the Pediatric Functional Disability Index (FDI). In addition, complete blood counts and serum chemistries were recorded at the start and end of treatment to evaluate safety. RESULTS: Fifteen patients (nine SBI, six placebo) completed the study. Both SBI and placebo groups reported nonstatistical reductions in stool frequency per week. The SBI group showed a significant reduction in stool frequency at weeks 1 and 2 but not at the end of treatment. The SBI group also demonstrated statistical improvements in abdominal pain and stool form by 3 weeks. The placebo group did not achieve similar improvements. The overall FDI and PedsQOL scores, as well as PedsQOL subscale scores for pain, discomfort when eating, diarrhea, worry about stomach aches, and communication, improved significantly in the SBI group, but not in the placebo group. No serious adverse events occurred. Serum chemistries and hemograms were normal at baseline and at the end of study in all patients. CONCLUSION: In this single-center, exploratory pilot study, we demonstrated that 10 g SBI per day was safe in children with d-IBS and improved symptoms. Larger studies, with longer treatment duration, seem warranted based on these initial positive results.

15.
Res Theory Nurs Pract ; 26(4): 279-89, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23556329

RESUMEN

The Anesthesia Clinical Research Unit (ACRU) at Boston Children's Hospital developed the integrated clinical research team model in 2009 as a framework to support the high ethical standards and team-based approach in pediatric anesthesia research which was already established within the department. The foundation of the model is built on interdisciplinary collaboration, communication, and integrity in the field of clinical research. Above all, the work of the ACRU is focused on the patients, families and community as a whole. In order to uphold these standards, each member of the ACRU has a clearly-defined role while still promoting the core fundamentals of teamwork and continuity of care. This department-wide, team-based approach to clinical research has proven to be effective in its resourcefulness and productivity in running numerous large projects concurrently within the department.


Asunto(s)
Anestesia , Investigación Biomédica , Modelos Organizacionales , Grupo de Atención al Paciente , Boston , Comunicación , Conducta Cooperativa , Hospitales Pediátricos/organización & administración
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA